Dr. Reddy's Laboratories (500124) Aperçu de l'action
Reddy's Laboratories Limited, avec ses filiales, est une entreprise pharmaceutique intégrée présente dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 1/6 |
| Performances passées | 2/6 |
| Santé financière | 5/6 |
| Dividendes | 5/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour 500124 à partir de nos contrôles de risques.
500124 Community Fair Values
Create NarrativeSee what 35 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Dr. Reddy's Laboratories Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | ₹1,275.05 |
| Plus haut sur 52 semaines | ₹1,377.95 |
| Plus bas sur 52 semaines | ₹1,149.00 |
| Bêta | 0.26 |
| Variation sur 1 mois | 0.39% |
| Variation sur 3 mois | -1.39% |
| Variation sur 1 an | -6.46% |
| Variation sur 3 ans | 32.69% |
| Variation sur 5 ans | 20.55% |
| Évolution depuis l'introduction en bourse | 37,357.35% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jun 05
500124: Diabetes And Oncology Launches Will Drive Future Upside Despite GST Disputes
Analysts have lifted their price target on Dr. Reddy's Laboratories from ₹1,615 to about ₹1,679, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple in their models. What's in the News R-Pharm Group and Dr. Reddy's agreed to introduce the anticancer drug toripalimab in Russia, with all finished dosage production to be localized at R-Pharm facilities, after Dr. Reddy's secured commercialization rights across 21 countries and launched the drug in India and Australia.
Mise à jour du récit • May 22
500124: Fair Outlook Will Balance Injectable Diabetes Launches And Compliance Developments
Analysts have nudged their fair value estimate for Dr. Reddy's Laboratories up from ₹1,314 to about ₹1,332. This change reflects updated assumptions around revenue growth, profit margins and future P/E expectations.Recent updates
Mise à jour du récit • Jun 05
500124: Diabetes And Oncology Launches Will Drive Future Upside Despite GST Disputes
Analysts have lifted their price target on Dr. Reddy's Laboratories from ₹1,615 to about ₹1,679, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple in their models. What's in the News R-Pharm Group and Dr. Reddy's agreed to introduce the anticancer drug toripalimab in Russia, with all finished dosage production to be localized at R-Pharm facilities, after Dr. Reddy's secured commercialization rights across 21 countries and launched the drug in India and Australia.Mise à jour du récit • May 22
500124: Fair Outlook Will Balance Injectable Diabetes Launches And Compliance Developments
Analysts have nudged their fair value estimate for Dr. Reddy's Laboratories up from ₹1,314 to about ₹1,332. This change reflects updated assumptions around revenue growth, profit margins and future P/E expectations.
Mise à jour du récit • May 03
500124: Future Tax Compliance And Regulatory Setbacks Will Curb Share Price Upside
Analysts have kept their fair value estimate for Dr. Reddy's Laboratories steady at ₹1,024, explaining that small adjustments to revenue growth, profit margin and future P/E assumptions did not materially change their overall price target view. What's in the News Health Canada granted Dr. Reddy's a Notice of Compliance for its generic Semaglutide Injection, allowing commercialization and sale in Canada.Mise à jour du récit • Apr 19
500124: Future Tax And Regulatory Compliance Issues Will Limit Upside Potential
Analysts have revised their price target for Dr. Reddy's Laboratories to ₹1,024, reflecting updated assumptions of higher revenue growth of 5.96%, a profit margin of 16.95% and a lower future P/E of 17.43x. What's in the News Launch of Obeda, an injectable semaglutide for type 2 diabetes in India, following Drugs Controller General of India approval for generic semaglutide.Mise à jour du récit • Apr 05
500124: Fair Outlook Will Balance Biosimilar Opportunity And Compliance Developments
Analysts have increased their price target on Dr. Reddy's Laboratories by about ₹13 to ₹1,314, citing updated assumptions that include a different discount rate, revised revenue growth and profit margin estimates, and an adjusted future P/E multiple. What's in the News Board meeting scheduled for March 24, 2026, to amend the Code of Practices and Procedures for Fair Disclosures of Un published Price Sensitive Information, signaling a focus on disclosure norms and compliance (company filing).Mise à jour du récit • Mar 21
500124: Biosimilar Pipeline Progress Will Drive Future Upside Despite GST Disputes
Analysts have maintained their price target for Dr. Reddy's Laboratories at ₹1,615. This reflects only minor adjustments to revenue growth, profit margin and forward P/E assumptions, rather than a change in the overall valuation view.Mise à jour du récit • Mar 07
500124: Biosimilar Approvals Will Drive Future Upside Despite Regulatory And Tax Overhang
Analysts have kept their price target for Dr. Reddy's Laboratories unchanged at ₹1,615, citing only marginal tweaks to revenue growth, profit margin and forward P/E assumptions that do not materially alter their valuation view. What's in the News The USFDA has accepted review of Dr. Reddy's 351(k) Biologics License Application for DRL_AB, a proposed interchangeable biosimilar to ORENCIA (abatacept) for multiple autoimmune indications, supported by analytical, PK and clinical data, including an ongoing Phase 3 trial (company announcement).Mise à jour du récit • Feb 21
500124: Biosimilar Pipeline And New Launches Will Drive Future Upside
Analysts have nudged their fair value estimate for Dr. Reddy's Laboratories slightly higher from about ₹1,611 to roughly ₹1,615 per share, reflecting updated assumptions on revenue growth, profit margins, and the future P/E multiple in their models. What's in the News US FDA accepted review of a 351(k) Biologics License Application for DRL_AB, a proposed interchangeable biosimilar to Orencia (abatacept), for multiple rheumatoid and arthritis indications in adults and children, backed by analytical, PK, and clinical data including Phase 1 PK similarity and an ongoing Phase 3 trial (company announcement).Mise à jour du récit • Feb 07
500124: Future Regulatory And Tax Compliance Risks Will Limit Upside Potential
Analysts have raised their fair value estimate for Dr. Reddy's Laboratories from ₹990 to ₹1,024, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E as key drivers of this change. What's in the News Launched OTC Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S., a generic equivalent to Extra Strength Pataday Once Daily Relief, for temporary relief of itchy eyes caused by allergens.Mise à jour du récit • Jan 23
500124: Biosimilar Approvals And New Launches Will Drive Future Upside
Analysts have trimmed their price target on Dr. Reddy's Laboratories slightly from ₹1,615 to about ₹1,611, reflecting updated views on future revenue growth, profit margins, and a higher assumed future P/E multiple. What's in the News Launched an over the counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S., a generic equivalent of Extra strength Pataday Once Daily Relief, targeting temporary relief of itchy eyes from allergens such as pollen, grass and animal dander (USFDA approval).Mise à jour du récit • Jan 06
500124: Biosimilar Approvals Will Support Future Upside As Regulatory Issues Remain Contained
Analysts have kept their fair value estimate for Dr. Reddy's Laboratories steady at ₹1,615, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions that they view as offsetting each other. What's in the News Dr. Reddy's received five separate orders from the GST Authority for tax demand, interest, and penalties related to alleged excess input tax credit for FY2018-19 to FY2022-23, with penalties of ₹1,89,30,110, ₹80,41,186, ₹3,52,95,063, ₹1,45,04,023 and ₹70,86,675 respectively.Mise à jour du récit • Dec 14
500124: Biosimilar Approvals Will Drive Future Upside Despite Slight Multiple Compression
Analysts have marginally lowered their price target on Dr. Reddy's Laboratories to ₹1,615 from ₹1,626, reflecting a slightly higher discount rate, while also factoring in stronger revenue growth, improved profit margins and a somewhat lower future P E multiple. What's in the News European Commission grants marketing authorization for AVT03, Dr. Reddy's and Alvotech's biosimilar to Prolia and Xgeva, with Dr. Reddy's holding exclusive commercialization rights in the U.S. and semi exclusive rights in Europe and the UK (company announcement) EMA's CHMP earlier issued a positive opinion recommending AVT03 for marketing authorization across the European Economic Area, with a separate submission planned to the UK MHRA under the International Recognition Procedure (company announcement) Dr. Reddy's receives an Establishment Inspection Report from the USFDA, with the inspection classified as Voluntary Action Indicated and officially closed (regulatory filing) Eisai and Dr. Reddy's reach a patent settlement allowing Dr. Reddy's to launch a generic version of cancer drug Lenvima in the U.S. from July 1, 2030, subject to certain contingencies (legal filing) Company launches Tegoprazan in India under the brand name PCAB to treat acid related gastrointestinal diseases, targeting a large and growing acid peptic disease population (product launch) Valuation Changes The fair value estimate has been reduced slightly to ₹1,615 from ₹1,625.93, reflecting a modestly more conservative outlook.Mise à jour du récit • Oct 27
Biosimilar Expansion And Legal Agreements Will Shape Future Market Opportunities
Analysts have revised their price target for Dr. Reddy's Laboratories upward from ₹1,287.37 to ₹1,300.62. This reflects renewed confidence driven by improved profit margin forecasts, despite marginally lower revenue growth expectations.Mise à jour du récit • Sep 04
Investments In Biosimilars And NRT Will Expand Market Reach, Yet Regulatory Hurdles May Persist
With both revenue growth and net profit margin forecasts steady, analysts maintained their fair value estimate for Dr. Reddy's Laboratories at ₹1287. What's in the News Dr. Reddy's Laboratories and Extrovis AG launched Fluorouracil Cream, 0.5% in the US as an authorized generic, approved by the USFDA.
Nouveau récit • Nov 13
Regulatory Hurdles And Rising Expenses Threaten To Squeeze Margins And Stifle Growth
Upfront costs from acquisitions and partnerships may pressure short-term earnings and compress net margins.Rendement pour les actionnaires
| 500124 | IN Pharmaceuticals | IN Marché | |
|---|---|---|---|
| 7D | 0.6% | 0.4% | -1.2% |
| 1Y | -6.5% | 5.5% | -5.1% |
Rendement vs Industrie: 500124 a sous-performé le secteur Indian Pharmaceuticals qui a rapporté 5.5 % au cours de l'année écoulée.
Rendement vs marché: 500124 a sous-performé le marché Indian qui a rapporté -5.1 % au cours de l'année écoulée.
Volatilité des prix
| 500124 volatility | |
|---|---|
| 500124 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.7% |
Cours de l'action stable: 500124 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Indian.
Volatilité au fil du temps: La volatilité hebdomadaire de 500124 ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1984 | 27,527 | Erez Israeli | www.drreddys.com |
Reddy's Laboratories Limited, avec ses filiales, est une société pharmaceutique intégrée opérant à l'échelle mondiale. Ses activités s'articulent autour des segments suivants : Global Generics, Pharmaceutical Services and Active Ingredients (PSAI) et Others. Le segment Global Generics de la société fabrique et commercialise des produits pharmaceutiques finis sur ordonnance et en vente libre qui sont commercialisés sous un nom de marque ou en tant que dosages génériques finis ayant une équivalence thérapeutique avec les formulations de marque, et s'engage dans l'activité biologique.
Dr. Reddy's Laboratories Limited Résumé des fondamentaux
| 500124 statistiques fondamentales | |
|---|---|
| Capitalisation boursière | ₹1.06t |
| Bénéfices(TTM) | ₹42.85b |
| Recettes(TTM) | ₹335.93b |
24.8x
Ratio P/E3.2x
Ratio P/SLe site 500124 est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| 500124 compte de résultat (TTM) | |
|---|---|
| Recettes | ₹335.93b |
| Coût des recettes | ₹158.67b |
| Marge brute | ₹177.26b |
| Autres dépenses | ₹134.41b |
| Les revenus | ₹42.85b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 51.46 |
| Marge brute | 52.77% |
| Marge bénéficiaire nette | 12.76% |
| Ratio dettes/capitaux propres | 16.5% |
Quelles ont été les performances à long terme de 500124?
Voir les performances historiques et les comparaisonsDividendes
0.6%
Rendement actuel des dividendes16%
Ratio de distributionLe site 500124 verse-t-il des dividendes fiables ?
Voir 500124 l'historique des dividendes et les indices de référence| Dr. Reddy's Laboratories dates des dividendes | |
|---|---|
| Date ex-dividende | Jul 10 2026 |
| Date de paiement du dividende | Aug 22 2026 |
| Jours jusqu'au dividende Ex | 28 days |
| Jours jusqu'à la date de paiement du dividende | 71 days |
Le site 500124 verse-t-il des dividendes fiables ?
Voir 500124 l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/11 23:56 |
| Cours de l'action en fin de journée | 2026/06/11 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Dr. Reddy's Laboratories Limited est couverte par 69 analystes. 37 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |